Duty exemptions will support better patient outcomes and encourage the integration of advanced medical technologies into the Indian healthcare landscape. Last week, India's Finance Minister Nirmala Sitharaman announced a tax waiver for three cancer drugs — trastuzumab deruxtecan, osimertinib and durvalumab — in the Union Budget for 2024-25. The 10 percent Integrated Goods and Service Tax (IGST) […]
No comments:
Post a Comment